EVOKE-03
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
- NCT05609968 ↗
- Active, not recruiting
- Merck Sharp & Dohme LLC
- Deep
We haven't built an HCP commentary report on EVOKE-03 (sacituzumab govitecan plus pembrolizumab in first-line PD-L1 TPS ≥50% metastatic non-small-cell lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on EVOKE-03 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 48 | |
| Podcasts | 7 | |
| YouTube | 6 |
The trial
ClinicalTrials.gov- Official title
- An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater Than or Equal to 50% Metastatic Non-small Cell Lung Cancer (KEYNOTE D46/EVOKE-03)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Sacituzumab Govitecan; Pembrolizumab
- Arms
- Pembrolizumab + Sacituzumab Govitecan · Experimental
- Pembrolizumab · Experimental
- Enrollment
- 614 (estimated)
- Primary outcomes
- Progression-Free Survival (PFS)
- Overall Survival (OS)
- Sponsor
- Merck Sharp & Dohme LLC with Gilead Sciences
- Start
- Feb 6, 2023
- Primary completion
- Jan 12, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05609968 · updated Dec 24, 2025